The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. THC is a agonist of BC receptors and chronic use of Cannabis may lead to tolerance of these receptors.

Events 48

Events THC Chronic Pain Sleep 48

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Christopher M.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Project CBD

MAY 3, 2023

She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. I don’t know that it’s a direct sleep agent, but when you are having less anxiety and less pain you likely will fall asleep a little bit easier and maybe sleep better.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

MedicalJane

DECEMBER 13, 2017

These changes included adding chronic pain and PTSD to its list of qualifying medical conditions. Chronic pain, on its own, is already responsible for more than 7,500 new patients joining New York’s MMJ program. This is a step forward for the state that was once criticized for its strict rules.

Programs 49

Programs Patients Chronic Pain Marijuana 49

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

OCTOBER 6, 2021

Preliminary in-vitro, ex-vivo, and in-vivo data demonstrated that AnQlar inhibits replication of SARS-CoV-2 and may inhibit viral spread as well as viral brain load at non-toxic concentrations. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Betsy Brod.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. The team focused its efforts on understanding whether owning an MMJ card impacted CUD, particularly in terms of chronic pain, insomnia, anxiety, or depressive symptoms.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Healer

JUNE 28, 2019

‘Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.’ Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. 006), mean worst pain (P =.011), Abstract: Medical Study .

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

DECEMBER 14, 2021

There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients. to bring innovation and precision to the growing UK medical cannabis market.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. RECENT DEVELOPMENTS.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Veriheal

OCTOBER 5, 2020

This bill also allows for dispensaries to “provide, disseminate, and publish educational and scientific material related to medical cannabis and its approved products and sponsor events about medical cannabis”. . Summary of Hawaiian Cannabis Regulations. Act 228 allows for the growth of cannabis for medical purposes. .

Edibles 52

Edibles Legalization Decriminalization Consumption 52

Cannabis Law Report

MAY 6, 2022

Examples of sellers’ language the FDA views as illegal are the following: “Our line of …CBD oil … is great for insomnia, epilepsy, MS, schizophrenia, and chronic pain.”. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. “In

THC 52

THC CBD Media Food 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MARCH 19, 2020

2 At the conclusion of the meeting, FDA stated that it would form an internal working group to study data gaps relating to CBD. As indicated by FDA’s recent announcement, the collection of data about the risks and benefits of CBD remains a priority for the agency. FDA submitted this report last week, as is discussed below.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

OCTOBER 26, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Green Relief

MAY 13, 2018

Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Preliminary data suggests that a synergistic combination of CBD and hypothermia may produce the best results. An estimated 4 million to 6 million Americans are on disability because of TBI. CBD for CTE. Complementary Therapies for TBI.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018.

Law 40

Law Seed-To-Sale Hemp Recreational 40